Pipeline watch · Reported as news

PP405: the follicle-reactivation drug everyone's watching

The most-discussed name in the hair-loss pipeline is a once-daily topical that tries to wake dormant follicles rather than fight hormones. Here's the evidence, and the honest gaps.

By the Editorial Team · Last updated June 10, 2026 · Medical review: pending — treat as education, not advice

Where it came from

PP405 traces to academic work at UCLA on the metabolism of hair-follicle stem cells. The company developing it, Pelage Pharmaceuticals, was founded in 2018 by UCLA scientists, building on research into why follicles cycle between dormancy and growth. That lineage matters for context: this is a mechanism that grew out of basic stem-cell biology, not a reformulation of an existing hair drug.

The mechanism, in plain language

Hair follicles cycle between a resting phase (telogen) and an active growth phase (anagen). A line of research found that the metabolic state inside follicle stem cells helps flip that switch: when these cells shift toward producing more lactate, they tend to activate. The foundational 2017 study in this area showed that increasing lactate production in mouse follicle stem cells accelerated their activation, while blocking it did the opposite.

PP405 is described as a topical inhibitor of the mitochondrial pyruvate carrier. The intended effect is to nudge follicle stem-cell metabolism toward that growth-promoting, lactate-favoring state — in effect, trying to wake follicles that have gone dormant rather than blocking the hormone (DHT) that drives pattern loss. If that distinction holds up in larger trials, it would make PP405 mechanistically complementary to the existing approved options rather than a replacement for them.

What the Phase 2a trial actually reported

In 2025, Pelage reported interim results from a randomized, placebo-controlled Phase 2a study in adults with androgenetic alopecia. Publicly reported details and company statements described:

• A trial enrolling roughly 78 men and women across a range of skin and hair types.
• Once-daily topical application for four weeks, with follow-up observation afterward.
• A met primary safety endpoint, with the drug reported as well tolerated and no systemic absorption detected in blood plasma.
• An efficacy signal reported by the company — including that a subset of male participants showed a meaningful increase in hair density versus baseline.

Read this carefully. Phase 2a is an early, primarily safety-focused stage. A four-week dosing window with a small sample produces a signal, not proof of durable, real-world benefit. The company has indicated a fuller data set would be presented at a future medical meeting — and peer-reviewed publication and independent scrutiny are what turn a promising signal into established knowledge.

What's still unknown

• Durability. Four weeks of dosing tells you little about whether gains hold over months or years, or whether benefits reverse on stopping (as minoxidil's do).
• Phase 3 outcome. Most drugs that look good at Phase 2 still fail somewhere before approval. A planned Phase 3 is a plan, not a result.
• Label and access. Even with success, the eventual approved use, patient population, and availability are unknown until regulators rule.
• Timeline. Pivotal trials take years. Any "coming soon" framing — from anyone — is speculation about a process that has not finished.

Development tracker

We keep a dated log of PP405's progress so this page stays current as the science develops. Newest first. Each entry separates what was reported from what it does and doesn't establish.

How to follow it without getting played

This is exactly the kind of story where hype outruns evidence. Our state-of-the-field guide lays out the questions that separate news from noise: what phase, what endpoint, how many participants, and whether the data is peer-reviewed. Apply them to every PP405 headline — including the optimistic ones. We'll update this page as the Phase 3 program and published data develop.